Reflow Medical Introduces Next-Gen Torqueable Microcatheters in U.S.

Reflow Medical Inc. has launched its next-generation Cora Flex and Cora Force Torqueable Microcatheters in the United States.

Designed for complex coronary interventions, the Cora Torqueable Microcatheters introduce enhancements focused on spinning freedom and torque transmission to support controlled navigation and lesion crossing in challenging anatomies.

The updated microcatheters incorporate refinements to hub design, shaft construction, and distal profile to improve handling, pushability, and trackability. “From an engineering perspective, we focused on optimizing rotational behavior, torque transmission, and overall handling characteristics,” Reflow Medical Engineering Vice President Outhit Bouasaysy said. “These enhancements reflect direct physician input and our targeted approach to building endovascular solutions to advance the treatment of challenging coronary lesions.”

The Cora Flex Torqueable Microcatheter is designed to support navigation in tortuous vessels, septals, and microchannels while the Cora Force Torqueable Microcatheter—featuring a metal tip—is engineered to provide additional pushability and tip force in more resistant, calcified, and fibrotic lesions, according to the company.

The devices are built on Cora Tech, a proprietary construction featuring a no-liner design with PTFE-coated coils to enable unrestricted torque rotation, combined with a stainless-steel braid intended to support controlled torque transmission and catheter stability. In addition to spinning freedom, the predictable torque transmission offers precise control, especially when navigating tortuous vessels.

“The new Cora Torqueable Microcatheters are truly next-generation devices that will become a standard in my daily practice,” said Garrett B. Wong, M.D., clinical professor of Medicine at the UC Davis Medical Center in Sacramento, Calif. “Both versions deliver outstanding performance, especially spinning freedom. I can rotate the catheter without the risk of guidewire lock-up, which is a major benefit when crossing challenging anatomies.”

Dr. Wong was among the physicians who provided real-world procedural feedback during the iterative development of the Cora Torqueable Microcatheters.

“The U.S. launch of the next-generation Cora platform represents an important step in expanding our coronary portfolio to support patients with coronary artery disease,” Reflow Medical Global Marketing Vice President Dejan Ilic stated.

Reflow Medical has recently expanded its presence in the coronary segment, including the presentation of first-in-human data from the DEEPER CORONARY study, evaluating the Spur Elute Coronary Sirolimus-Eluting Retrievable Stent System for treating coronary in-stent restenosis.

Reflow Medical is a global company developing technologies that address unmet clinical needs in the endovascular treatment of complex cardiovascular disease. The company’s portfolio includes coronary and peripheral microcatheters, crossing catheters, and its proprietary Retrievable Scaffold Therapy (RST) platform. The coronary Cora Catheters line is approved by the U.S. Food and Drug Administration (FDA). The peripheral product line includes Wingman, Spex, Spex LP, and Spur, which have both FDA clearance and CE Mark registration. Reflow Medical is headquartered in San Clemente, Calif.